Abstract:IL‐17A, the effector cytokine of T helper (Th) 17 cells, plays a crucial role in the pathogenesis of psoriasis. The Notch1 and PI3K/AKT signaling pathways are implicated in Th17 cell differentiation and IL‐17A production. The present study aimed to evaluate the regulatory effect of the Notch1/hairy and enhancer of split 1 (Hes1)‐PTEN/AKT/IL‐17A feedback loop on Th17 cell differentiation via the PI3K/AKT inhibitor LY294002 in a mouse model of psoriasis. Mice were randomly divided into 3 groups: a control group, a model group [5% imiquimod (IMQ)‐induced group] and an intervention group (5% IMQ‐induced plus LY294002‐treated group). Skin structural characteristics were recorded and evaluated by hematoxylin and eosin staining. The weights of the spleens and inguinal lymph nodes were measured. Th17 cell percentage, as well as the mRNA and protein expression levels of Notch1, Notch1 intracellular domain (NICD1), Hes1, PTEN, AKT, phosphorylated (p)‐AKT, mTOR complex 1 (mTORC1), p‐mTORC1, S6 kinase (S6K)1, S6K2 and IL‐17A were detected in skin samples of the three experimental groups. Additionally, splenic mononuclear cells from model mice were treated by 10 and 50 μM LY294002 to further evaluate its regulatory effect on Notch1/Hes1‐PTEN/AKT/IL‐17A feedback loop. Increased Th17 cell percentage, increased expression of Notch1, NICD1, Hes1, AKT, p‐AKT, mTORC1, p‐mTORC1, S6K1, S6K2 and IL‐17A, and decreased PTEN levels were observed in model mice alongside marked psoriasis‐like skin inflammation, splenomegaly and lymphadenopathy. LY294002 treatment significantly alleviated the severity of psoriasis‐like skin inflammation in the intervention mice, attenuated the degree of epidermal hyperplasia and dermal inflammatory cell infiltration, and mitigated splenomegaly and lymphadenopathy. In addition, LY294002 treatment reversed the increased Th17 cell percentage, as well as the increased expression of Notch1, NICD1, Hes1, AKT, p‐AKT, mTORC1, p‐mTORC1, S6K1, S6K2 and IL‐17A, and the decreased expression of PTEN. In vitro study from 5% IMQ‐induced mouse splenic mononuclear cells presented that high dose of LY294002 exerted more obviously regulatory effect on Notch1/Hes1‐PTEN/AKT/IL‐17A feedback loop. The current findings suggested that the Notch1/Hes1‐PTEN/AKT/IL‐17A feedback loop regulates Th17 cell differentiation within the disease environment of psoriasis. Blocking the Notch1/Hes1‐PTEN/AKT/IL‐17A feedback loop may thus be a potential therapeutic method for management of psoriatic inflammation.

Topical histone deacetylase 1 inhibitor Entinostat ameliorates psoriasiform dermatitis through suppression of IL-17A response

Topical histone deacetylase inhibitor remetinostat improves IMQ-induced psoriatic dermatitis via suppressing dendritic cell maturation and keratinocyte differentiation and inflammation

Discovery of Janus Kinase and Histone Deacetylase Dual Inhibitors as a New Strategy to Treat Psoriasis

New Treatment Addressing the Pathogenesis of Psoriasis

LY294002 ameliorates psoriatic skin inflammation in mice via blocking the Notch1/Hes1-PTEN/AKT/IL-17A feedback loop

Tetrastigma hemsleyanum polysaccharides alleviate imiquimod-induced psoriasis-like skin lesions in mice by modulating the JAK/STAT3 signaling pathway

Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis

Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-alpha/IFN-gamma-induced inflammatory response in keratinocytes and T cell-derived IL-17

Topical application of endothelin receptor a antagonist attenuates imiquimod-induced psoriasiform skin inflammation

A therapeutic strategy of parthenolide in improving imiquimod-induced psoriasis-like skin inflammation targeting IL-36/NETs through skin transdermal therapeutic system

Acitretin-Conjugated Dextran Nanoparticles Ameliorate Psoriasis-like Skin Disease at Low Dosages

Development of a Topical Treatment for Psoriasis Targeting RORγ: From Bench to Skin

NETs contribute to psoriasiform skin inflammation: A novel therapeutic approach targeting IL-36 cytokines by a small molecule tetrahydroxystilbene glucoside

WB518, a Novel STAT3 Inhibitor, Effectively Alleviates IMQ and TPA-induced Animal Psoriasis by Inhibiting STAT3 Phosphorylation and Keratin 17

Hesperidin Inhibits Keratinocyte Proliferation and Imiquimod-Induced Psoriasis-Like Dermatitis Via the IRS-1/ERK1/2 Pathway

Notch1/Hes1‐PTEN/AKT/IL‐17A feedback loop regulates Th17 cell differentiation in mouse psoriasis‐like skin inflammation

IBI112, a Selective Anti-Il23p19 Monoclonal Antibody, Displays High Efficacy in IL-23-induced Psoriasiform Dermatitis.

Nintedanib ameliorates imiquimod-induced psoriasis in mice by inhibiting NF-κB and VEGFR2 signaling

443 EZH2-dependent Epigenetic Modulation of Histone H3 Lysine-27 Contributes to Psoriasis by Promoting Keratinocyte Proliferation

Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study

A single-cell atlas of IL-23 inhibition in cutaneous psoriasis distinguishes clinical response